Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lenvatinib Oral Product
Lenvatinib Product · 1 trial · 3 indications
Pathological Complete Response will be determined by pathologist examination of tissue after neoadjuvant treatment and resection
| Arm | Type | Description |
|---|---|---|
| Lenvatinib plus Pembrolizumab | EXPERIMENTAL | Participants with Merkel cell carcinoma amenable to complete resection will receive two cycles (6 weeks) of therapy with the combination of lenvatinib plus pembrolizumab and then proceed to planned resection within 2-4 weeks following completion of cycle 2. Following surgical recovery and completion of adjuvant radiation therapy (if indicated), treatment will resume with pembrolizumab monotherapy with intent to complete 17 cycles total of pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| Lenvatinib Oral Product | DRUG | 20mg of Lenvatinib will be taken orally once daily |
| Pembrolizumab | DRUG | 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks. |
Inclusion Criteria: * Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of Merkel cell carcinoma will be enrolled in this study. The clinical stage of the patient must be stage II, III, or IV (AJCC 8th edition) a...
Lenvatinib Product is an investigational small molecule being studied for the treatment of Merkel Cell Carcinoma, also known as neuroendocrine carcinoma of the skin or trabecular carcinoma of the skin. It is currently in Phase 2 clinical development for this indication.
Lenvatinib Product is a kinase inhibitor, belonging to the -tinib class of drugs. It works by targeting kinases, which are enzymes involved in cell signaling and growth. This mechanism is being evaluated in the context of Merkel Cell Carcinoma.
Lenvatinib Product is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug for Merkel Cell Carcinoma.
Lenvatinib Product is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing trial is active but not recruiting participants.
Lenvatinib Product is being studied in a Phase 2 clinical trial with the identifier NCT04869137, titled 'Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma.' The trial is enrolling 26 participants in the United States and is active but not recruiting.
Yes, Lenvatinib Product is also known as Lenvatinib Oral Product. Both names refer to the same investigational drug being developed by Merck & Company, Inc. for Merkel Cell Carcinoma.